arGentis Pharmaceuticals LLCannounced that the company has licensed a third treatment for Dry Eye Syndrome (DES) now designated ARG103. This is a continuance of arGentis’ licensing partnership with the Southern College of Optometry (SCO) and ARG103 becomes the third prospective therapy for DES that utilizes the transdermal delivery of an active pharmaceutical ingredient to affected glands via application of a cream or gel to the outer, upper and lower eyelids. ARG103 will broaden the reach of arGentis’ transdermal ocular technology, which includes ARG101 for use in menopausal women and ARG102, a progesterone-based formulation that treats DES in younger women and men.

SynergEyes Inc. has recently launched a revolutionary hybrid contact lens designed for people who need further vision correction after undergoing refractive vision surgery, such as LASIK. SynergEyes(R) PS (post-surgical) is also designed for patients who have experienced some type of corneal trauma or suffer from certain degenerative vision conditions. Approved for marketing by the FDA, SynergEyes PS hybrid contact lenses bond a “hard” and “soft” contact lens together resulting in a one-of-a-kind vision correction option that provides crisp, clear vision for surgically altered corneas in a comfortable, healthy contact lens.